Eye Meds Now

 Quick Ophthalmic Drug Search

229 items found
NEOMYCIN, POLYMYXIN B, BACITRACIN AND HYDROCORTISONE (neomycin sulfate (3.5 mg/g) – polymyxin B sulfate (10,000 units/g) – bacitracin zinc (400 units/g) – hydrocortisone acetate (1%) ophthalmic ointment)
Prescription
Topical
Ointment
Antibiotic–Steroid Combination Medications
Indications/Usage:

Indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists.

Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. 

The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. 

The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus, streptococci, including: Streptococcus pneumoniae; Escherichia coli; Haemophilus influenzae; Klebsiella/Enterobacter species Neisseria species; Pseudomonas aeruginosa. The product does not provide adequate coverage against Serratia marcescens.

This medication has a broad FDA approval for "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Steroid-responsive inflammatory ocular conditions: 

  • Apply the ointment in the affected eye every 3 – 4 hours, depending on the severity of the condition.
  • Not more than 8 grams should be prescribed initially and the prescription should not be refilled without further evaluation as outlined in PRECAUTIONS in package insert.

How Supplied:  
  • 3.5 g tubes

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 59° – 77°F (15° – 25°C).


NEOSPORIN OPHTHALMIC OINTMENT (neomycin sulfate (3.5 mg/g) – polymyxin B sulfate (10,000 units/g) – bacitracin zinc (400 units/g) ophthalmic ointment)
Prescription
Topical
Ointment
Antibiotics
Indications/Usage:

Indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.


Typical Dosing:  

Superficial infections of the external eye and its adnexa:

  • Apply the ointment every 3 – 4 hours for 7 – 10 days, depending on the severity of the infection.

►Recurrent corneal erosion:

  • Follow normal dosing patterns; typically 2 – 3 times/day.

How Supplied:  
  • 3.5 g tubes

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 59° – 77°F (15° – 25°C).


NEOSPORIN OPHTHALMIC SOLUTION (neomycin sulfate (0.175%) – polymyxin B sulfate (10,000 units/mL) – gramicidin (0.0025%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis.


Typical Dosing:  

Superficial infections of the external eye and its adnexa:

  • Instill 1 – 2 drops into the affected eye(s) every 4 hours for 7 – 10 days.
  • In severe infections, dosage may be increased to as much as 2 drops every hour.

How Supplied:  
  • 10 mL bottles

Preservatives:  

thimerosal


Storage:  
  • Store at 59° – 77°F (15° – 25°C).
  • Protect from light.


NEVANAC (nepafenac (0.1%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
NSAIDS
Indications/Usage:

Indicated for the treatment of pain and inflammation associated with cataract surgery.


Typical Dosing:  

Pain and inflammation associated with cataract surgery: 

  • Shake well before use.
  • 1 drop should be applied to the affected eye(s) 3 times daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the post-operative period.
  • May be administered in conjunction with other topical ophthalmic medications such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics.
  • If more than 1 topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.

How Supplied:  
  • 3 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 36° – 77°F (2° – 25°C).


Assistance: Payment Assistance

NORCO (hydrocodone bitartrate (5 mg; 7.5 mg; 10 mg) – acetaminophen (325 mg) tablets)
Opioid
Prescription
Oral
Tablets
Opiates/Opioids
Indications/Usage:

Indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use

Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [See WARNINGS in package insert], reserve NORCO® for use in patients for whom alternative treatment options (e.g., nonopioid analgesics):

  • Have not been tolerated, or are not expected to be tolerated.
  • Have not provided adequate analgesia, or are not expected to provide adequate analgesia.

Typical Dosing:  

Pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

  • Important dosage and administration instructions:
    • Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [See WARNINGS in package insert].
    • Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse [See WARNINGS in package insert].
    • Follow patients closely for respiratory depression, especially within the first 24 – 72 hours of initiating therapy and following dosage increases with NORCO® and adjust the dosage accordingly [See WARNINGS in package insert].
  • Initial dosage:
    • NORCO® 5/325: The usual adult dosage is 1 or 2 tablets every 4 – 6 hours as needed for pain. The total daily dosage should not exceed 8 tablets.
    • NORCO® 7.5/325 and NORCO® 10/325: The usual adult dosage is 1 tablet every 4 – 6 hours as needed for pain. The total daily dosage should not exceed 6 tablets.
  • Conversion from other opioids to NORCO®: 
    • There is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dosage of NORCO® .  
    • It is safer to underestimate a patient’s 24-hour NORCO® dosage than to overestimate the 24-hour NORCO dosage and manage an adverse reaction due to overdose.
  • Conversion from NORCO® to Extended-Release Hydrocodone:
    • The relative bioavailability of hydrocodone from NORCO® compared to extended-release hydrocodone products is unknown, so conversion to extended-release products must be accompanied by close observation for signs of excessive sedation and respiratory depression.
  • Titration and maintenance of therapy:
    • Individually titrate NORCO® to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving NORCO® to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse [See WARNINGS in package insert]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.
    • If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the NORCO® dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.
  • Safe reduction or discontinuation of NORCO®:
    • Do not abruptly discontinue NORCO® in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.
    • When a decision has been made to decrease the dose or discontinue therapy in an opioid-dependent patient taking NORCO®, there are a variety of factors that should be considered, including the dose of NORCO® the patient has been taking, the duration of treatment, the type of pain being treated, and the physical and psychological attributes of the patient. It is important to ensure ongoing care of the patient and to agree on an appropriate tapering schedule and follow-up plan so that patient and provider goals and expectations are clear and realistic. When opioid analgesics are being discontinued due to a suspected substance use disorder, evaluate and treat the patient, or refer for evaluation and treatment of the substance use disorder. Treatment should include evidence-based approaches, such as medication assisted treatment of opioid use disorder. Complex patients with co-morbid pain and substance use disorders may benefit from referral to a specialist.
    • There are no standard opioid tapering schedules that are suitable for all patients. Good clinical practice dictates a patient-specific plan to taper the dose of the opioid gradually. For patients on NORCO® who are physically opioid-dependent, initiate the taper by a small enough increment (e.g., no greater than 10% to 25% of the total daily dose) to avoid withdrawal symptoms, and proceed with dose-lowering at an interval of every 2 to 4 weeks. Patients who have been taking opioids for briefer periods of time may tolerate a more rapid taper.
    • It may be necessary to provide the patient with lower dosage strengths to accomplish a successful taper. Reassess the patient frequently to manage pain and withdrawal symptoms, should they emerge. Common withdrawal symptoms include restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other signs and symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate. If withdrawal symptoms arise, it may be necessary to pause the taper for a period of time or raise the dose of the opioid analgesic to the previous dose, and then proceed with a slower taper. In addition, monitor patients for any changes in mood, emergence of suicidal thoughts, or use of other substances.
    • When managing patients taking opioid analgesics, particularly those who have been treated for a long duration and/or with high doses for chronic pain, ensure that a multimodal approach to pain management, including mental health support (if needed), is in place prior to initiating an opioid analgesic taper. A multimodal approach to pain management may optimize the treatment of chronic pain, as well as assist with the successful tapering of the opioid analgesic [See WARNINGS; Withdrawal, DRUG ABUSE AND DEPENDENCE in package insert].

How Supplied:  
  • 5/325 (5 mg hydrocodone bitartrate – 325 mg acetaminophen) tablets
  • 7.5/325 (7.5 mg hydrocodone bitartrate – 325 mg acetaminophen) tablets
  • 10/325 (10 mg hydrocodone bitartrate – 325 mg acetaminophen) tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Store securely and dispose of properly [See PRECAUTIONS; Information for Patients in package insert].


OCUFLOX (ofloxacin (0.3%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:
Conjunctivitis:
Gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Pseudomonas aeruginosa
Gram-negative bacteria: Enterobacter cloacae, Haemophilus influenzae, Proteus mirabilis, Pseudomonas aeruginosa
Corneal ulcers:
Gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa, Serratia marcescens*
Anaerobic species: Propionibacterium acnes

*Efficacy for this organism was studied in fewer than 10 infections.


Typical Dosing:  

Bacterial conjunctivitis, recommended:

  • Days 1 and 2: Instill 1 – 2 drops every 2 – 4 hours in the affected eye(s).
  • Days 3 – 7: Instill 1 – 2 drops 4 times daily.

Bacterial corneal ulcer, recommended:

  • Days 1 and 2: Instill 1 – 2 drops into the affected eye(s) every 30 minutes, while awake. Awaken at approximately 4 and 6 hours after retiring and instill 1 – 2 drops.
  • Days 3 through 7 – 9: Instill 1 – 2 drops hourly, while awake.
  • Days 7 – 9 through treatment completion: Instill 1 – 2 drops, 4 times daily.

►Recurrent corneal erosion:

  • Follow normal dosing patterns.

How Supplied:  
  • 5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59° – 77°F (15°– 25°C).


OFLOXACIN (ofloxacin (0.3%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antibiotics
Indications/Usage:

Indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below:
Conjunctivitis:
Gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Pseudomonas aeruginosa
Gram-negative bacteria: Enterobacter cloacae, Haemophilus influenzae, Proteus mirabilis, Pseudomonas aeruginosa
Corneal ulcers:
Gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa, Serratia marcescens*
Anaerobic species: Propionibacterium acnes

*Efficacy for this organism was studied in fewer than 10 infections.


Typical Dosing:  

Bacterial conjunctivitis, recommended:

  • Days 1 and 2: Instill 1 – 2 drops every 2 – 4 hours in the affected eye(s).
  • Days 3 – 7: Instill 1 – 2 drops 4 times daily.

Bacterial corneal ulcer, recommended:

  • Days 1 and 2: Instill 1 – 2 drops into the affected eye(s) every 30 minutes, while awake. Awaken at approximately 4 and 6 hours after retiring and instill 1 – 2 drops.
  • Days 3 through 7 – 9: Instill 1 – 2 drops hourly, while awake.
  • Days 7 – 9 through treatment completion: Instill 1 – 2 drops, 4 times daily.

►Recurrent corneal erosion, recommended:

  • Follow normal dosing patterns.

How Supplied:  
  • 5 mL bottles
  • 10 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 59° – 77°F (15°– 25°C).


OLOPATADINE (olopatadine hydrochloride (0.1%; 0.2%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antihistamines and Mast Cell Stabilizer Combinations
Indications/Usage:

Indicated for the treatment of the signs and symptoms of allergic conjunctivitis.


Typical Dosing:  

Allergic conjunctivitis, recommended:

  • 0.1% Ophthalmic solution:
    • Instill 1 drop in each affected eye 2 times per day at an interval of 6 – 8 hours.
  • 0.2% Ophthalmic solution:
    • Instill 1 drop in each affected eye once a day.

How Supplied:  
  • 0.1% Ophthalmic solution:
    • 5 mL bottles
  • 0.2% Ophthalmic solution:
    • 2.5 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 39° – 77°F (4° – 25°C).


OMIDRIA (phenylephrine (1%) – ketorolac (0.3%) intraocular solution)
Prescription
Injectable
Intraocular
Other Medications
Indications/Usage:

Is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing post-operative ocular pain.


Typical Dosing:  

Cataract surgery or intraocular lens replacement:

  • Must be diluted prior to intraocular use.
  • 4 mL is diluted in 500 mL of ocular irrigating solution.
  • Irrigation solution is to be used as needed for the surgical procedure for a single patient. 
  • The storage period for the diluted product is not more than 4 hours at room temperature or 24 hours under refrigerated conditions. 
  • Do not use if the solution is cloudy or if it contains particulate matter.

How Supplied:  
  • 4 mL vials (for single patient use)

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 68˚ to 77˚F (20˚ – 25˚C).
  • Protect from light.


Assistance: Payment Assistance

Special Purchasing Instructions: How to Purchase

OMNIPRED (prednisolone acetate (1%) ophthalmic suspension)
Prescription
Topical
Ophthalmic Suspension
Allergy Corticosteroids, Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated in steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.

This medication has a broad FDA approval for "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe:

  • SHAKE WELL BEFORE USING.
  • Instill 2 drops topically in the eye(s) 4 times daily.
  • In cases of bacterial infections, concomitant use of anti-infective agents is mandatory.
  • Care should be taken not to discontinue therapy prematurely.
  • If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated (See PRECAUTIONS in package insert).
  • The dosing of Omnipred® suspension may be reduced, but care should be taken not to discontinue therapy prematurely.
  • In chronic conditions, withdrawal of treatment should be carried out by gradually decreasing the frequency of applications.

How Supplied:  
  • 5 mL bottles
  • 10 mL bottles
  • 15 mL bottles (generic only)

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 46° – 75°F (8° – 24°C) in an UPRIGHT position.


OPCON-A (naphazoline hydrochloride (0.027%) – pheniramine maleate (0.3%) ophthalmic solution)
Over the Counter
Topical
Ophthalmic Solution
Ocular Decongestants/Vasoconstrictors
Indications/Usage:

Used for the temporary relief of itching and redness caused by: pollen; ragweed; grass; animal hair and dander.


Typical Dosing:  

Itching and redness caused by: pollen; ragweed; grass; animal hair and dander:

  • Adults and children  6 years of age:
    • Instill 1 – 2 drops in the affected eye(s) up to 4 times daily.
  • Children < 6 years of age:
    • Ask a doctor.

How Supplied:  
  • 15 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 68°– 77°F (20°– 25°C).
  • Protect from light.
  • Use before expiration date marked on the carton or bottle.
  • Package is child-resistant.


ORAPRED ODT (prednisolone sodium phosphate (10 mg; 15 mg; 30 mg) tablets, orally disintegrating)
Prescription
Oral
Oral Disintegrating Tablets
Allergy Corticosteroids, Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated in the treatment of sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.

This medication has a broad FDA approval for "ocular inflammatory conditions." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "ocular inflammatory conditions." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids, recommended:

  • Adult initial dose, recommended:
    • The initial dose may vary from 10 – 60 mg (prednisolone base) per day, depending on the specific disease entity being treated.
    • In situations of less severity, lower doses will generally suffice while in selected patients higher initial doses may be required.
    • The initial dosage should be maintained or adjusted until a satisfactory response is noted.
    • If after a reasonable period of time, there is a lack of satisfactory clinical response, Orapred should be discontinued and the patient placed on other appropriate therapy.
  • Pediatric:
    • The range of initial doses is 0.14 – 2 mg/kg/day in 3 – 4 divided doses (4 – 60 mg/m2bsa/day). The initial dose may vary depending on the specific disease entity being treated.
  • Dosage should be individualized according to the severity of the disease and the response of the patient. For pediatric patients, the recommended dosage should be governed by the same considerations rather than strict adherence to the ratio indicated by age or body weight.
  • Do not break or use partial Orapred ODT tablets. Use an appropriate formulation of prednisolone if indicated dose cannot be obtained using Orapred ODT. This may become important in the treatment of conditions that require tapering doses that cannot be adequately accommodated by Orapred ODT, e.g., tapering the dose below 10 mg.
  • Additional information for Dosing and Administration is in Notes below.

How Supplied:  
  • 10 mg orally disintegrating tablets
  • 15 mg orally disintegrating tablets
  • 30 mg orally disintegrating tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Excursions permitted to 59° – 86°F (15° – 30°C).
  • Protect from moisture.
  • Do not break or use partial Orapred ODT tablets. 
  • Keep out of the reach of children.


OTC TEAR SUPPLEMENTS
Over the Counter
Indications/Usage:

For information on OTC tear supplements, click HERE. See OTC Tears link at the top of the page to sort by active ingredient, preservatives or viscosity.


How Supplied:  

N/A



OXERVATE (cenegermin-bkbj (0.002%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Other Medications
Indications/Usage:

Indicated for the treatment of neurotrophic keratitis.


Typical Dosing:  

►Neurotrophic keratitis, recommended:

  • Instill 1 drop in the affected eye(s), 6 times a day at 2 hour intervals for 8 weeks.
  • Contact lenses should be removed before applying OXERVATE and may be reinserted 15 minutes after administration.
  • If a dose is missed, treatment should be continued as normal, at the next scheduled administration.
  • If more than 1 topical ophthalmic product is being used, administer the eye drops at least 15 minutes apart to avoid diluting products. Administer OXERVATE 15 minutes prior to using any eye ointment, gel or other viscous eye drops.
  • Additional information on Preparation for Administration is in Notes below.

How Supplied:  
  • Supplied in a weekly Delivery System Kit containing the following:
    • 7 multiple-dose vials of OXERVATE in an insulated pack (1 vial per day of the week)
    • 7 vial adapters
    • 42 pipettes
    • 42 sterile disinfectant wipes 
    • Dose recording card (1)
    • Extra adapter (1) pipettes (3) and wipes (3) are included as spares.

Preservatives:  

None listed in package insert.


Storage:  
  • Within 5 hours of leaving the pharmacy, store the weekly carton in the refrigerator between 36° – 46°F (2° – 8°C) for up to 14 days.
  • Opened vials may be stored in the original weekly carton in the refrigerator between 36° – 46°F (2° – 8°C) or at room temperature up to 77°F (25°C), for up to 12 hours [See Dosage and Administration (2.1) in package insert].
  • Do not refreeze.
  • Do not shake the vial.
  • Discard any unused portion after 12 hours.


Assistance: Payment Assistance

Special Purchasing Instructions: How to Purchase

OZURDEX (dexamethasone (0.7 mg) intravitreal implant)
Prescription
Injectable
Intravitreal
Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO); the treatment of non-infectious uveitis affecting the posterior segment of the eye; and for the treatment of diabetic macular edema.


Typical Dosing:  

Macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO), posterior segment uveitis, or diabetic macular edema:

  • 1 implant (0.7 mg) via intravitreal injection; may repeat in contralateral eye.
  • Additional information for Dosage and Administration is in Notes below.

How Supplied:  
  • 0.7 mg intravitreal implants

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 59° – 86°F (15°– 30°C).


Assistance: Payment Assistance

Special Purchasing Instructions: How to Purchase

PAREMYD (hydroxyamphetamine hydrobromide (1%) – tropicamide (0.25%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Cycloplegic and Mydriatic Combinations
Indications/Usage:

Indicated for mydriasis in routine diagnostic procedures and in conditions where short-term pupil dilation is desired. PAREMYD® provides clinically significant mydriasis with partial cycloplegia.


Typical Dosing:  

►Mydriasis for diagnostic procedures and in conditions requiring short-term pupil dilation:

  • Instill 1 – 2 drops in the conjunctival sac. The onset of action occurs within 15 minutes followed by maximum effect within 60 minutes. Clinically significant dilation, inhibition of pupillary light response, and partial cycloplegia last 3 hours.
  • Mydriasis will reverse spontaneously with time, typically in 6 to 8 hours. However, in some cases, complete recovery may take up to 24 hours.

How Supplied:  
  • 15 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store between 68º – 77ºF (20ºC – 25ºC).
  • Protect from light.


PATADAY ONCE DAILY RELIEF (olopatadine hydrochloride (0.2%) ophthalmic solution)
Over the Counter
Topical
Ophthalmic Solution
Antihistamines and Mast Cell Stabilizer Combinations
Indications/Usage:

Temporarily relieves itchy eyes due to pollen, ragweed, grass, animal hair and dander.


Typical Dosing:  

Allergic conjunctivitis, recommended:

  • Adults and children ≥ 2 years of age:
    • Put 1 drop in the affected eye(s) once daily, no more than once per day.
    • If using other ophthalmic products while using this product, wait at least 5 minutes between each product.
  • Children < 2 years of age: consult a doctor

How Supplied:  
  • 2.5 mL bottles
  • 0.5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store between 36° – 77°F (2° – 25°C).
  • Replace cap after each use.


Assistance: Payment Assistance

PATADAY TWICE DAILY RELIEF (olopatadine hydrochloride (0.1%) ophthalmic solution)
Over the Counter
Topical
Ophthalmic Solution
Antihistamines and Mast Cell Stabilizer Combinations
Indications/Usage:

Temporarily relieves itchy and red eyes due to pollen, ragweed, grass, animal hair and dander.


Typical Dosing:  

 ►Allergic conjunctivitis, recommended:

  • Adults and children ≥ 2 years of age:
    • Put 1 drop in the affected eye(s) twice daily, every 6 – 8 hours, no more than twice per day.
    • If using other ophthalmic products while using this product, wait at least 5 minutes between each product.
  • Children < 2 years of age: consult a doctor. 

How Supplied:  
  • 5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store between 39° – 77°F (4° – 25°C).
  • Replace cap after each use.


Assistance: Payment Assistance

PAZEO (olopatadine hydrochloride (0.7%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antihistamines and Mast Cell Stabilizer Combinations
Indications/Usage:

Indicated for the treatment of ocular itching associated with allergic conjunctivitis.


Typical Dosing:  

Itching associated with allergic conjunctivitis, recommended:

  • Instill 1 drop in each affected eye once a day.

How Supplied:  
  • 2.5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 36° – 77°F (2° – 25°C).


Assistance: Payment Assistance

PERCOCET (oxycodone hydrochloride (2.5 mg; 5 mg; 7.5 mg; 10 mg) – acetaminophen (325 mg) tablets)
Opioid
Prescription
Oral
Tablets
Opiates/Opioids
Indications/Usage:

Indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use:

Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [See WARNINGS in package insert], reserve PERCOCET for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]:

  • Have not been tolerated, or are not expected to be tolerated.
  • Have not provided adequate analgesia, or are not expected to provide adequate analgesia.

Typical Dosing:  

Pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate:

  • Initial adult dosage: 
    • Initiate treatment with 2.5 mg/325 mg tablets, with 1 – 2 tablets every 6 hours as needed for pain.
    • The total daily dose of acetaminophen should not exceed 4 grams. 
  • Usual adult dosage by strength:
    • 2.5 mg/325 mg tablets:
      • 1 – 2 tablets every 6 hours as needed for pain.
      • Maximum 12 tablets per day.
    • 5 mg/325 mg tablets:
      • 1 tablet every 6 hours as needed for pain.
      • Maximum 12 tablets per day.
    • 7.5 mg/325 mg tablets:
      • 1 tablet every 6 hours as needed for pain.
      • Maximum 8 tablets per day.
    • 10 mg/325 mg tablets:
      • 1 tablet every 6 hours as needed for pain.
      • Maximum 6 tablets per day.
  • Titration and maintenance of therapy:
    • Individually titrate PERCOCET to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving PERCOCET to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse [See WARNINGS in package insert]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.
    • If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the PERCOCET dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.
  • Conversion to extended-release oxycodone:
    • The relative bioavailability of Oxycodone Hydrochloride and Acetaminophen Tablets or Oral Solution compared to extended-release oxycodone is unknown, so conversion to extended-release oxycodone must be accompanied by close observation for signs of excessive sedation and respiratory depression.
  • Safe reduction or discontinuation:
    • Do not abruptly discontinue PERCOCET in patients who may be physically dependent on opioids. Rapid discontinuation of opioid analgesics in patients who are physically dependent on opioids has resulted in serious withdrawal symptoms, uncontrolled pain, and suicide. Rapid discontinuation has also been associated with attempts to find other sources of opioid analgesics, which may be confused with drug-seeking for abuse. Patients may also attempt to treat their pain or withdrawal symptoms with illicit opioids, such as heroin, and other substances.
    • Consult package insert for additional information.
  • Additional important Dosage and Administration instructions in Notes below.

How Supplied:  
  • 2.5/325 (2.5 mg oxycodone hydrochloride – 325 mg acetaminophen) tablets
  • 5/325 (5 mg oxycodone hydrochloride – 325 mg acetaminophen) tablets
  • 7.5/325 (7.5 mg oxycodone hydrochloride – 325 mg acetaminophen) tablets
  • 10/325 (10 mg oxycodone hydrochloride – 325 mg acetaminophen) tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Protect from moisture and light.
  • Store securely and dispose of properly [See PRECAUTIONS/Information for Patients in package insert].


229 items found